IL33 and Alzheimer disease: The −26999 G/A mutation in the distal promoter of IL1RL1 (the receptor for IL‐33; ST2) leads to the increased expression of soluble ST2 (IL‐33 decoy receptor), preferential activation of TH2 cells, high total IgE, and an increased odds ratio (1.87) to develop AD.67